Published On: September 10th, 2024

Share

Published On: September 10th, 2024

Share

Photo of Arbor Research Collaborative for Health office building.

Arbor Research Collaborative for Health (Arbor Research) is proud to announce that its wholly-owned, small-business subsidiary, Arbor Research LLC, received its first competitive prime contract award. The award expands the organization’s 25-year history doing mission-impactful work in chronic disease and beyond.

Arbor Research was awarded the National Cancer Institute (NCI) Center for Global Health (CGH) Coordination, Data Analysis, and Technical Support IDIQ. This IDIQ provides services for NCI CGH through technical support for their research, coordination, and evaluation activities; data and portfolio analysis; production of accompanying reports; and science and technical writing, presentations, and documentation. The IDIQ contract ceiling is $9.9 million.

“We are excited by this opportunity to support the important work of the NCI and CGH’s cancer control initiatives directly. This work is a natural extension of our strong record of clinical research network coordination, cancer epidemiology, and international collaboration,” said John Graff, PhD, the Arbor Research Project Director, and cancer epidemiologist.

Immediately, Arbor Research will launch two task orders for NCI.

Global Cancer Research and Control Seminar Series (GCRCSS): Arbor Research will provide logistics, planning, execution, and post-event services for the GCRCSS.

Logistical and Technical Support for Implementation Science Consortium Activities (ICSA): Arbor Research will implement qualitative and quantitative analytic research studies, including provide study design, build data collection tools and web-based surveys, perform data analyses, and disseminate study results via reports, scientific and public presentations, and peer-reviewed manuscripts

Arbor Research partnered with Synergy Enterprises for this IDIQ pursuit.

“This award is a testament to our ongoing commitment to delivering innovative, impactful research that addresses critical global cancer control challenges, while providing value and agility to NCI’s mission,” said Christopher Spera, PhD, President and CEO of Arbor Research.

Related Posts